Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Sleep-Related Painful Erections: A Meta-Analysis on the Pathophysiology and Risks and Benefits of Medical Treatments.

Vreugdenhil S, Weidenaar AC, de Jong IJ, van Driel MF.

J Sex Med. 2018 Jan;15(1):5-19. doi: 10.1016/j.jsxm.2017.11.006. Epub 2017 Dec 6. Review.

PMID:
29208538
2.

Sleep-Related Painful Erections-A Case Series of 24 Patients Regarding Diagnostics and Treatment Options.

Vreugdenhil S, Weidenaar AC, de Jong IJ, van Driel MF.

Sex Med. 2017 Dec;5(4):e237-e243. doi: 10.1016/j.esxm.2017.09.001. Epub 2017 Oct 21.

3.

Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.

Weidenaar AC, Ter Elst A, Kampen KR, Meeuwsen-de Boer T, Kamps WA, Schuringa JJ, de Bont ES.

Mol Cancer Res. 2013 Apr;11(4):339-48. doi: 10.1158/1541-7786.MCR-12-0113. Epub 2013 Feb 7.

4.

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling.

Weidenaar AC, ter Elst A, Kampen KR, Meeuwsen-de Boer TG, de Jonge HJ, Scherpen FJ, den Dunnen WF, Kamps WA, de Bont ES.

Br J Cancer. 2011 Dec 6;105(12):1856-63. doi: 10.1038/bjc.2011.460. Epub 2011 Nov 1.

5.

High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow.

Weidenaar AC, ter Elst A, Koopmans-Klein G, Rosati S, den Dunnen WF, Meeuwsen-de Boer T, Kamps WA, Vellenga E, de Bont ES.

Cell Oncol (Dordr). 2011 Aug;34(4):289-96. doi: 10.1007/s13402-011-0017-9. Epub 2011 Apr 6.

6.

A new perspective on transcriptional system regulation (TSR): towards TSR profiling.

Fehrmann RS, de Jonge HJ, Ter Elst A, de Vries A, Crijns AG, Weidenaar AC, Gerbens F, de Jong S, van der Zee AG, de Vries EG, Kamps WA, Hofstra RM, Te Meerman GJ, de Bont ES.

PLoS One. 2008 Feb 20;3(2):e1656. doi: 10.1371/journal.pone.0001656.

7.

Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.

de Jonge HJ, Weidenaar AC, Ter Elst A, Boezen HM, Scherpen FJ, Bouma-Ter Steege JC, Kaspers GJ, Goemans BF, Creutzig U, Zimmermann M, Kamps WA, de Bont ES.

Clin Cancer Res. 2008 Feb 1;14(3):924-30. doi: 10.1158/1078-0432.CCR-07-1821.

8.

Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.

Weidenaar AC, de Jonge HJ, Fidler V, ter Elst A, Meeuwsen-de Boer T, Douwes J, Bouma-ter Steege JC, Hählen K, Kamps WA, de Bont ES.

Anticancer Drugs. 2008 Jan;19(1):45-54.

PMID:
18043129

Supplemental Content

Loading ...
Support Center